PKCϵ Is Required for KRAS-Driven Lung Tumorigenesis
Open Access
- 29 September 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 80 (23) , 5166-5173
Abstract
Non–small cell lung cancer (NSCLC) is the most frequent subtype of lung cancer and remains a highly lethal malignancy and one of the leading causes of cancer-related deaths worldwide. Mutant KRAS is the prevailing oncogenic driver of lung adenocarcinoma, the most common histologic form of NSCLC. In this study, we examined the role of PKCε, an oncogenic kinase highly expressed in NSCLC and other cancers, in KRAS-driven tumorigenesis. Database analysis revealed an association between PKCε expression and poor outcome in patients with lung adenocarcinoma specifically harboring KRAS mutations. A PKCε-deficient, conditionally activatable allele of oncogenic Kras (LSL-KrasG12D;PKCε−/− mice) demonstrated the requirement of PKCε for Kras-driven lung tumorigenesis in vivo, which was consistent with impaired transformed growth reported in PKCε-deficient KRAS-dependent NSCLC cells. Moreover, PKCε-knockout mice were found to be less susceptible to lung tumorigenesis induced by benzo[a]pyrene, a carcinogen that induces mutations in Kras. Mechanistic analysis using RNA sequencing revealed little overlap for PKCε and KRAS in the control of genes and biological pathways relevant in NSCLC, suggesting that a permissive role of PKCε in KRAS-driven lung tumorigenesis may involve nonredundant mechanisms. Our results thus, highlight the relevance and potential of targeting PKCε for lung cancer therapeutics. Significance: These findings demonstrate that KRAS-mediated tumorigenesis requires PKCε expression and highlight the potential for developing PKCε-targeted therapies for oncogenic RAS-driven malignancies.Keywords
All Related Versions
Funding Information
- NIH (R01-ES026023, R01-CA189765, R01-CA196232)
- NIH (R01-CA193602, R01-CA222503)
- American Lung Association (LCD400095)
- NIH (T32ES019851)
- Argentine National Agency of Scientific and Technological Promotion (PICT-2015-0149)
- MD Anderson Cancer Center (P30 CA16672)
This publication has 25 references indexed in Scilit:
- Non-Small Cell Lung Carcinoma Cell Motility, Rac Activation and Metastatic Dissemination Are Mediated by Protein Kinase C EpsilonPLOS ONE, 2012
- Proteins kinase Cɛ is required for non-small cell lung carcinoma growth and regulates the expression of apoptotic genesOncogene, 2011
- Differential Regulation of Gene Expression by Protein Kinase C Isozymes as Determined by Genome-wide Expression AnalysisJournal of Biological Chemistry, 2011
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell SurvivalCancer Cell, 2009
- Protein Kinase Cε Is Overexpressed in Primary Human Non–Small Cell Lung Cancers and Functionally Required for Proliferation of Non–Small Cell Lung Cancer Cells in a p21/Cip1-Dependent MannerCancer Research, 2007
- Protein kinase Cε and development of squamous cell carcinoma, the nonmelanoma human skin cancerMolecular Carcinogenesis, 2006
- An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysisNature Genetics, 2004
- Protein Kinase C Promotes Apoptosis in LNCaP Prostate Cancer Cells through Activation of p38 MAPK and Inhibition of the Akt Survival PathwayJournal of Biological Chemistry, 2003
- PKCε is a permissive link in integrin-dependent IFN-γ signalling that facilitates JAK phosphorylation of STAT1Nature Cell Biology, 2003
- The genetic basis of susceptibility to lung tumors in miceToxicology, 1989